Physician profile
Alexander Douglas Lee
NPI 1275227654
$2,366.72
in general payments reported to CMS, 2019-2025
20 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $49.98 · 2024: $538 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.63 |
| Education | $181.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $622.10 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Biotech, INC. | $482.14 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $316.37 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $291.72 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $129.98 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.31 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $62.53 | 2024-2025 | Omvoh |
| Organon LLC | $52.10 | 2023-2024 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $52.00 | 2025 | Voquezna |
| Celgene Corporation | $44.33 | 2024 | Zeposia |
| Aimmune Therapeutics, INC. | $28.28 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $27.36 | 2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $27.13 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $23.85 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $23.37 | 2025 | Iqirvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.73 | 2025 | |
| Ardelyx, INC. | $16.97 | 2025 | Ibsrela |
| Vivus LLC | $16.25 | 2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $15.67 | 2025 | |
| Invivyd INC | $13.53 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.